Latest NMDA receptor antagonists Stories
People with depression who have tried many different treatments without success may have one more option in the near future: laughing gas.
WASHINGTON, July 23, 2014 /PRNewswire-USNewswire/ -- For critically ill patients arriving at the emergency department, the drug ketamine can safely provide analgesia, sedation and amnesia for
There is new hope for people suffering from depression.
- Lead NMDA Receptor Modulator GLYX-13 Shows Robust and Sustained Antidepressant Effects with Repeat Dosing and Is Well-Tolerated in Subjects with Difficult-to-Treat Depression - EVANSTON,
Researchers from Mount Sinai Demonstrate Proof of Concept for New, Rapidly-Acting Pharmacotherapy for Treatment of PTSD New York, NY (PRWEB) April 16, 2014
Schizophrenia is a severe disease for which there is still no effective medical treatment.
Mount Sinai Team Cautiously Optimistic That Door Could Swing Open to A New Antidepressant Drug Class New York, NY (PRWEB) April 08, 2014 A research team
BOSTON, April 7, 2014 /PRNewswire/ -- Ketanetics, LLC, a Massachusetts-based company founded by physicians, is expanding the Ketamine infusion centers it operates beyond Massachusetts and New
The street drug ketamine is now being looked at for its therapeutic value as a new study from UK researchers at Oxford University has found that relatively small doses of the drug are effective in treating depression.
Data shows that dextromethorphan exerts antidepressant-like actions mediated at least in part through sigma-1 receptors ALISO VIEJO, Calif., March 20, 2014 /PRNewswire/ -- Avanir
- Large; stout; burly.